MediciNova (MNOV) News Today $2.07 -0.05 (-2.36%) (As of 12/24/2024 04:01 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.comStockNews.com began coverage on MediciNova in a report on Wednesday. They issued a "hold" rating for the company.December 25 at 2:06 AM | marketbeat.comMediciNova (NASDAQ:MNOV) Share Price Passes Above 200-Day Moving Average - Should You Sell?MediciNova (NASDAQ:MNOV) Stock Price Passes Above 200-Day Moving Average - Should You Sell?December 17, 2024 | marketbeat.comMediciNova (NASDAQ:MNOV) Now Covered by StockNews.comStockNews.com began coverage on shares of MediciNova in a research note on Tuesday. They set a "hold" rating for the company.December 17, 2024 | marketbeat.comMNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial…December 9, 2024 | msn.comMediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.comStockNews.com began coverage on shares of MediciNova in a report on Monday. They issued a "hold" rating for the company.December 9, 2024 | marketbeat.comMediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MNDDecember 5, 2024 | globenewswire.comMediciNova Inc.December 5, 2024 | wsj.comD. Boral Capital Initiates Coverage of MediciNova (MNOV) with Buy RecommendationDecember 3, 2024 | msn.comMediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.comStockNews.com began coverage on MediciNova in a report on Sunday. They issued a "hold" rating for the company.December 1, 2024 | marketbeat.comMediciNova, Inc.: MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to StockholdersNovember 20, 2024 | finanznachrichten.deMediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to StockholdersNovember 20, 2024 | finance.yahoo.comMediciNova provides update in letter to stockholdersNovember 20, 2024 | markets.businessinsider.comMediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.comStockNews.com initiated coverage on shares of MediciNova in a research report on Friday. They issued a "hold" rating on the stock.November 15, 2024 | marketbeat.comMediciNova granted Notice of Allowance for MN-001 patent by USPTONovember 14, 2024 | markets.businessinsider.comMediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the LiverNovember 14, 2024 | globenewswire.comMediciNova notified of settlement in Sanofi Novartis litigationNovember 12, 2024 | markets.businessinsider.comMediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-NovartisNovember 11, 2024 | globenewswire.comMediciNova (NASDAQ:MNOV) Shares Pass Above Two Hundred Day Moving Average - Here's WhyMediciNova (NASDAQ:MNOV) Stock Passes Above 200-Day Moving Average - Time to Sell?November 7, 2024 | marketbeat.comMediciNova (NASDAQ:MNOV) Shares Cross Above Two Hundred Day Moving Average - Should You Sell?MediciNova (NASDAQ:MNOV) Stock Crosses Above Two Hundred Day Moving Average - Time to Sell?October 30, 2024 | marketbeat.comMediciNova announces update of Phase 2/3 MN-166 trial at NEALS meetingOctober 24, 2024 | markets.businessinsider.comMediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)October 23, 2024 | globenewswire.comMediciNova (NASDAQ:MNOV) Research Coverage Started at StockNews.comStockNews.com began coverage on shares of MediciNova in a research note on Tuesday. They issued a "hold" rating on the stock.October 22, 2024 | marketbeat.comMediciNova (NASDAQ:MNOV) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comMediciNova (NASDAQ:MNOV) shareholders have endured a 73% loss from investing in the stock five years agoOctober 7, 2024 | finance.yahoo.comMNOV: MN-166 to be Evaluated in NIH-Sponsored Expanded Access Trial in ALS…September 30, 2024 | msn.comShort Interest in MediciNova, Inc. (NASDAQ:MNOV) Increases By 19.3%MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) saw a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 224,600 shares, an increase of 19.3% from the August 31st total of 188,200 shares. Currently, 0.5% of the shares of the company are short sold. Based on an average daily volume of 39,300 shares, the days-to-cover ratio is presently 5.7 days.September 30, 2024 | marketbeat.comMediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)September 30, 2024 | globenewswire.comMediciNova (NASDAQ:MNOV) Stock Price Crosses Above Two Hundred Day Moving Average of $1.42MediciNova (NASDAQ:MNOV) Shares Pass Above 200 Day Moving Average of $1.42September 28, 2024 | marketbeat.comMediciNova, Inc. (NASDAQ:MNOV) Sees Large Increase in Short InterestMediciNova, Inc. (NASDAQ:MNOV - Get Free Report) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 188,200 shares, an increase of 104.3% from the August 15th total of 92,100 shares. Approximately 0.4% of the company's stock are sold short. Based on an average daily trading volume, of 40,500 shares, the days-to-cover ratio is presently 4.6 days.September 15, 2024 | marketbeat.comMediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MNDSeptember 9, 2024 | globenewswire.comMediciNova (NASDAQ:MNOV) Stock Price Crosses Above 200-Day Moving Average of $1.36MediciNova (NASDAQ:MNOV) Share Price Passes Above 200-Day Moving Average of $1.36September 4, 2024 | marketbeat.comMediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) MeetingSeptember 3, 2024 | globenewswire.comMediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID ConditionAugust 29, 2024 | globenewswire.comMediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth PlansAugust 28, 2024 | finance.yahoo.comMNOV Sep 2024 2.500 call (MNOV240920C00002500)August 20, 2024 | finance.yahoo.comMediciNova, Inc. (MNOV)July 26, 2024 | finance.yahoo.comMediciNova, Inc. (NASDAQ:MNOV) Short Interest UpdateMediciNova, Inc. (NASDAQ:MNOV - Get Free Report) was the recipient of a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 110,700 shares, a decline of 18.4% from the May 31st total of 135,600 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 34,200 shares, the days-to-cover ratio is presently 3.2 days.June 29, 2024 | marketbeat.comMediciNova Chief Business Officer David H. Crean, Ph.D.June 20, 2024 | globenewswire.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid CancerJune 5, 2024 | globenewswire.comMediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024June 3, 2024 | globenewswire.comShort Interest in MediciNova, Inc. (NASDAQ:MNOV) Decreases By 25.5%MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totalling 158,600 shares, a decline of 25.5% from the April 30th total of 212,900 shares. Approximately 0.3% of the company's stock are short sold. Based on an average daily volume of 35,700 shares, the short-interest ratio is presently 4.4 days.May 30, 2024 | marketbeat.comMediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic ConditionsMay 28, 2024 | globenewswire.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye CancerMay 20, 2024 | stockhouse.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye CancerMay 20, 2024 | globenewswire.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress SyndromeMay 14, 2024 | globenewswire.comMediciNova, Inc.: MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)May 7, 2024 | finanznachrichten.deMediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)May 7, 2024 | globenewswire.comMediciNova (NASDAQ:MNOV) investors are sitting on a loss of 89% if they invested five years agoApril 30, 2024 | finance.yahoo.comMediciNova, Inc. (NASDAQ:MNOV) Short Interest Down 26.0% in AprilMediciNova, Inc. (NASDAQ:MNOV - Get Free Report) was the target of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 247,000 shares, a decrease of 26.0% from the March 31st total of 333,600 shares. Based on an average daily volume of 49,400 shares, the days-to-cover ratio is presently 5.0 days. Currently, 0.5% of the shares of the company are sold short.April 27, 2024 | marketbeat.comMediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)April 2, 2024 | globenewswire.com Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. MNOV Media Mentions By Week MNOV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNOV News Sentiment▼0.370.56▲Average Medical News Sentiment MNOV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNOV Articles This Week▼11▲MNOV Articles Average Week Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KRRO News Today CDXC News Today TKNO News Today AURA News Today ALMS News Today AKBA News Today IGMS News Today TSHA News Today CYRX News Today RGNX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNOV) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediciNova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNOV Stock Alerts